✦ LIBER ✦

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

✍ Scribed by M.J Elliott; R.N Maini; M Feldmann; J.R Kalden; C Antoni; J.S Smolen; B Leeb; F.C Breedveld; J.D Macfarlane; J.A Bijl; J.N Woody

Book ID: 118554571
Publisher: The Lancet
Year: 1994
Tongue: English
Weight: 797 KB
Volume: 344
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(94)90628-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized double-blind comparison of ch

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy

✍ Filip Van den Bosch; Elli Kruithof; Dominique Baeten; Annemie Herssens; Filip de 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

## Abstract ## Objective To confirm in a placebo‐controlled trial the safety and efficacy profile of infliximab in short‐term treatment of patients with active spondylarthropathy (SpA). ## Methods Forty patients with active SpA were randomly assigned to receive an intravenous loading dose (weeks

Infliximab (chimeric anti-tumour necrosi

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

✍ Ravinder Maini; E William St Clair; Ferdinand Breedveld; Daniel Furst; Joachim K 📂 Article 📅 1999 🏛 The Lancet 🌐 English ⚖ 133 KB

Repeated therapy with monoclonal antibod

Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

✍ M.J. Elliott; R.N. Maini; M. Feldmann; A. Long-Fox; P. Charles; J.A. Bijl; J.N. 📂 Article 📅 1994 🏛 The Lancet 🌐 English ⚖ 438 KB

Double-blind randomised controlled trial

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

✍ Edward Abraham; Antonio Anzueto; Guillermo Gutierrez; Sidney Tessler; Gerry San 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 672 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease

✍ B. G. Feagan; W. J. Sandborn; J. P. Baker; F. Cominelli; L. R. Sutherland; C. O 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB

Golimumab in patients with active rheuma

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

✍ Josef S Smolen; Jonathan Kay; Mittie K Doyle; Robert Landewé; Eric L Matteson; J 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 222 KB